Adult Dosing

Fine facial wrinkles, mottled facial pigmentation, benign facial lentigines (Cream)

• Apply a pea-sized amount to lightly cover the entire face, including the eyelids if desired, qhs

Psoriasis (Gel)

• Start by applying 0.05%, with strength increased to 0.1% (if tolerable), in the evenings, to psoriatic lesions, using enough (2 mg/cm²) to cover only the lesion with a thin film to no >20% of body surface area

Acne (Gel)

• Apply a thin film of 0.1% (2 mg/cm²) once daily, in the evenings, to the skin where acne lesions appear

Note:

• Remove makeup before applying cream to the face
• If the face is washed or a bath or shower is taken prior to application, the skin should be dry before applying the cream
• If emollients or moisturizers are used, they can be applied either before or after application of tazarotene cream ensuring that the first cream or lotion has absorbed into the skin and has dried completely

Acne(Foam)

• Apply 0.1% (2 mg/cm²) once daily, in the evenings, to the skin where acne lesions appear

Note:

• Foam is not for oral, ophthalmic, or intravaginal use
• Face should be washed with a mild cleanser and allowed to dry prior to application of foam
• If redness, peeling, or discomfort occurs, reduce frequency of application or temporarily interrupt the treatment. Resume the treatment once irritation subsides, and discontinue if irritation persists

Pediatric Dosing

Fine facial wrinkles, mottled facial pigmentation, benign facial lentigines (Cream)

• 17 yrs: Apply a pea-sized amount to lightly cover the entire face, including the eyelids if desired, qhs

Psoriasis (Gel)

• 12 yrs: Start by applying 0.05%, with strength increased to 0.1% (if tolerable), in the evenings, to psoriatic lesions, using enough (2 mg/cm²) to cover only the lesion with a thin film to no >20% of body surface area

Acne (Gel)

• 12 yrs: Apply a thin film of 0.1% (2 mg/cm²) once daily, in the evenings, to the skin where acne lesions appear

Note:

• Cream: Safety and effectiveness in pediatric patients <17 yrs of age have not been established
• Gel: Safety and effectiveness in pediatric patients <12 yrs of age have not been established
• Remove makeup before applying cream to the face
• If the face is washed or a bath or shower is taken prior to application, the skin should be dry before applying the cream
• If emollients or moisturizers are used, they can be applied either before or after application of tazarotene cream ensuring that the first cream or lotion has absorbed into the skin and has dried completely

Acne(Foam)

• 12 years: Apply 0.1% (2 mg/cm²) once daily, in the evenings, to the skin where acne lesions appear

Note:

• Foam is not for oral, ophthalmic, or intravaginal use
• Face should be washed with a mild cleanser and allowed to dry prior to application of foam
• If redness, peeling, or discomfort occurs, reduce frequency of application or temporarily interrupt the treatment. Resume the treatment once irritation subsides, and discontinue if irritation persists

Cream

• Adjunctive agent for use in the mitigation (palliation) of facial fine wrinkling, facial mottled hyper- and hypopigmentation, and benign facial lentigines in patients who use comprehensive skin care and sunlight avoidance programs

Gel

• Topical treatment of patients with stable plaque psoriasis of up to 20% body surface area involvement
• Topical treatment of patients with facial acne vulgaris of mild to moderate severity

Foam

• Topical treatment of acne vulgaris in patients 12 years of age

• Hypersensitivity to any of the ingredients of the product
• Pregnancy

• N/A

Renal Dose Adjustment

• Renal impairment: No dose adjustments

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustments

See Supplemental Patient Information

• Women of child-bearing potential should be warned about the potential harm to the fetus and advised to use adequate birth-control measures during therapy. A negative pregnancy test should be obtained 2 weeks prior to treatment; treatment should begin during a normal menstrual period
• Patients should be advised to contact their physicians or a poison control center, in case of accidental swallowing
• Do not share with others, even if their skin problem appears to be similar to yours
• For external use only; rinse thoroughly with water if there is contact with the eyes
• Should not be applied on eczematous skin until the eczema has fully recovered, because it may cause severe irritation
• Avoid exposure to sunlight unless deemed medically necessary because of heightened burning susceptibility. Patients with sunburn should not use until complete recovery
• Use sunscreens (minimum SPF of 15) and protective clothing during treatment, especially if you are sensitive to sunlight or at risk of considerable exposure to sunlight
• Use with caution in patients taking photosensitizing drugs, because of increased risk of augmented photosensitivity
• Safety of use over more than 20% of body surface area has not been established in psoriasis or acne
• Patients may experience excessive pruritus, burning, skin redness, or peeling during therapy. If such reactions occur, discontinue the drug until the integrity of the skin is restored or reduce the dose to an interval the patient can tolerate
• Weather extremes, such as wind or cold, may be more irritating to patients treated with tazarotene
• Lentigo maligna should not be treated with tazarotene cream; facial pigmented lesions of concern should be appropriately assessed by a qualified physician
• Closely monitor frequency of application by careful observation of the clinical therapeutic response and skin tolerance. Efficacy has not been established for less than once daily dosing frequencies

Caution: Use cautiously in

• Lactation

Supplemental Patient Information

• Advise patients to gently wash their face with a mild soap and dry it before applying cream
• Inform patients that the tazarotene cream does not remove or prevent wrinkles, reverse photoaging, repair sun-damaged skin, or restore more youthful skin

Pregnancy Category:X

Breastfeeding: Safety unknown; manufacturer advises caution.

• DERM: Pruritus, burning/stinging, erythema, worsening of psoriasis, irritation, skin pain, rash, desquamation, irritant contact dermatitis, skin inflammation, fissuring, bleeding, dry skin, skin discoloration, cheilitis, acne, localized edema
• HYPERSENSITIVITY: Photosensitivity
• MISC: Teratogenicity

• Retinoid prodrug; exact mechanism of action in the treatment of psoriasis, acne, or in the palliative management of dermatologic changes (e.g., fine wrinkling, mottled hypo or hyperpigmentation, and benign lentigines) has not been determined
• Minimal systemic absorption after topical application
• Prodrug undergoes esterase hydrolysis to form its active metabolite, tazarotenic acid
• Metabolized by skin and liver; CYP450: unknown
• Excretion: urine, feces
• Half-life: 18 hrs

US Trade Name(s)

• Avage
• Tazorac
• Fabior

US Availability

Avage

• CRE: 0.1%

Tazorac

• CRE: 0.05%
• CRE: 0.1%
• GEL: 0.05%
• GEL: 0.1 %

Fabior

• FOAM: 0.1 %

Canadian Trade Name(s)

• Tazorac

Canadian Availability

Tazorac

• CRE: 0.05%
• CRE: 0.1%
• GEL: 0.05%
• GEL: 0.1 %

UK Trade Name(s)

• Zorac

UK Availability

Zorac

• GEL: 0.05%
• GEL: 0.1 %

Australian Trade Name(s)

• Zorac

Australian Availability

Zorac

• CRE: 0.05%
• CRE: 0.1%

Dermatologic

Dermatologic Topical Agents

Retinoid Prodrug

Pricing data from www.DrugStore.com in U.S.A.

• Tazorac 0.1 % GEL [Tube] (ALLERGAN DERMATOLOGICS)
  100 % = $819.96
  300 % = $2419.92
• Tazorac 0.05 % GEL [Tube] (ALLERGAN DERMATOLOGICS)
  100 % = $750.95
  300 % = $2229.96
• Tazorac 0.05 % CREA [Tube] (ALLERGAN DERMATOLOGICS)
  60 % = $464.97
  180 % = $1358.01
• Tazorac 0.1 % CREA [Tube] (ALLERGAN DERMATOLOGICS)
  60 % = $501.01
  180 % = $1420.96
• Tazorac 0.05 % CREA [Tube] (ALLERGAN DERMATOLOGICS)
  30 % = $219.99
  90 % = $634.95
• Avage 0.1 % CREA [Tube] (ALLERGAN DERMATOLOGICS)
  30 % = $245.98
  90 % = $716.97
• Tazorac 0.1 % GEL [Tube] (ALLERGAN DERMATOLOGICS)
  30 % = $250.98
  90 % = $699.99
• Tazorac 0.05 % GEL [Tube] (ALLERGAN DERMATOLOGICS)
  30 % = $209.98
  90 % = $605.94
• Tazorac 0.1 % CREA [Tube] (ALLERGAN DERMATOLOGICS)
  30 % = $245.98
  90 % = $680

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.